Jeffrey W.  Albers net worth and biography

Jeffrey Albers Biography and Net Worth

Jeff has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. In 2014, he joined Blueprint Medicines as Chief Executive Officer and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), including vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics, Kymera Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the board of advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

What is Jeffrey W. Albers' net worth?

The estimated net worth of Jeffrey W. Albers is at least $17.61 million as of March 7th, 2024. Mr. Albers owns 165,017 shares of Blueprint Medicines stock worth more than $17,608,964 as of June 19th. This net worth estimate does not reflect any other assets that Mr. Albers may own. Learn More about Jeffrey W. Albers' net worth.

How do I contact Jeffrey W. Albers?

The corporate mailing address for Mr. Albers and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Jeffrey W. Albers' contact information.

Has Jeffrey W. Albers been buying or selling shares of Blueprint Medicines?

Jeffrey W. Albers has not been actively trading shares of Blueprint Medicines in the last ninety days. Most recently, Jeffrey W. Albers sold 25,073 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a transaction totalling $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares of the company's stock, valued at $15,365,644. Learn More on Jeffrey W. Albers' trading history.

Who are Blueprint Medicines' active insiders?

Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.

Are insiders buying or selling shares of Blueprint Medicines?

In the last twelve months, insiders at the biotechnology company sold shares 28 times. They sold a total of 225,100 shares worth more than $19,391,574.83. The most recent insider tranaction occured on June, 5th when insider Percy H Carter sold 4,000 shares worth more than $420,520.00. Insiders at Blueprint Medicines own 4.2% of the company. Learn More about insider trades at Blueprint Medicines.

Information on this page was last updated on 6/5/2024.

Jeffrey W. Albers Insider Trading History at Blueprint Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2024Sell25,073$87.28$2,188,371.44176,050View SEC Filing Icon  
3/7/2024Sell11,033$90.69$1,000,582.77165,017View SEC Filing Icon  
1/25/2024Sell25,000$81.91$2,047,750.00176,050View SEC Filing Icon  
11/30/2023Sell5,000$70.55$352,750.00176,050View SEC Filing Icon  
11/24/2023Sell15,000$67.51$1,012,650.00176,050View SEC Filing Icon  
11/3/2023Sell1,485$60.13$89,293.05176,050View SEC Filing Icon  
11/1/2023Sell3,881$60.02$232,937.62176,050View SEC Filing Icon  
9/28/2023Sell6,898$50.17$346,072.66176,050View SEC Filing Icon  
8/25/2023Sell10,000$50.16$501,600.00176,050View SEC Filing Icon  
3/6/2023Sell9,793$45.67$447,246.31173,450View SEC Filing Icon  
12/5/2022Sell20,000$50.09$1,001,800.00183,243View SEC Filing Icon  
8/22/2022Sell8,410$70.54$593,241.40183,243View SEC Filing Icon  
8/19/2022Sell1,590$70.02$111,331.80183,243View SEC Filing Icon  
8/16/2022Sell20,000$68.41$1,368,200.00183,243View SEC Filing Icon  
8/8/2022Sell10,000$70.07$700,700.00183,243View SEC Filing Icon  
4/6/2022Sell5,000$70.11$350,550.00183,243View SEC Filing Icon  
11/15/2021Sell30,000$114.50$3,435,000.00View SEC Filing Icon  
8/19/2021Sell25,000$92.68$2,317,000.00View SEC Filing Icon  
5/12/2021Sell25,000$92.69$2,317,250.00179,948View SEC Filing Icon  
10/7/2020Sell5,000$99.17$495,850.00146,434View SEC Filing Icon  
5/12/2020Sell20,000$64.67$1,293,400.00161,434View SEC Filing Icon  
3/23/2020Sell20,000$52.10$1,042,000.00141,434View SEC Filing Icon  
11/18/2019Sell8,256$75.42$622,667.5266,961View SEC Filing Icon  
11/8/2019Sell11,744$74.56$875,632.6466,961View SEC Filing Icon  
8/19/2019Sell20,000$81.73$1,634,600.0048,961View SEC Filing Icon  
6/17/2019Sell5,000$99.06$495,300.0033,961View SEC Filing Icon  
6/12/2019Sell20,000$84.75$1,695,000.0048,961View SEC Filing Icon  
3/15/2019Sell20,000$86.39$1,727,800.0048,961View SEC Filing Icon  
11/5/2018Sell20,000$63.49$1,269,800.0020,000View SEC Filing Icon  
8/6/2018Sell20,000$70.59$1,411,800.0020,000View SEC Filing Icon  
5/7/2018Sell20,000$78.90$1,578,000.0020,000View SEC Filing Icon  
3/2/2018Sell20,000$92.57$1,851,400.0020,000View SEC Filing Icon  
11/6/2017Sell30,000$70.31$2,109,300.00View SEC Filing Icon  
8/8/2017Sell30,000$49.62$1,488,600.0018,272View SEC Filing Icon  
8/7/2017Sell20,000$49.08$981,600.0018,272View SEC Filing Icon  
6/28/2017Sell20,000$50.47$1,009,400.0047,920View SEC Filing Icon  
8/8/2016Sell17,000$22.86$388,620.0076,494View SEC Filing Icon  
6/3/2016Sell17,000$20.03$340,510.0092,486View SEC Filing Icon  
4/6/2016Sell17,000$20.42$347,140.00109,486View SEC Filing Icon  
See Full Table

Jeffrey W. Albers Buying and Selling Activity at Blueprint Medicines

This chart shows Jeffrey W Albers's buying and selling at Blueprint Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Blueprint Medicines Company Overview

Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $106.71
Low: $102.55
High: $107.12

50 Day Range

MA: $100.40
Low: $85.18
High: $108.78

2 Week Range

Now: $106.71
Low: $43.89
High: $111.02


572,080 shs

Average Volume

488,804 shs

Market Capitalization

$6.68 billion

P/E Ratio


Dividend Yield